Characteristics of emerging new autoimmune diseases after COVID-19 vaccination: A sub-study by the COVAD group.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shumnalieva Russka, Ravichandran Naveen, Hannah Jennifer, Javaid Mahnoor, Darooka Naitica, Roy Debaditya, Gonzalez Daniel E, Velikova Tsvetelina, Milchert Marcin, Kuwana Masataka, Joshi Mrudula, Gracia-Ramos Abraham Edgar, Boyd Peter, Yaadav Praggya, Cheng Karen, Kobert Linda, Cavagna Lorenzo, Sen Parikshit, Day Jessica, Makol Ashima, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo V, Saha Sreoshy, Parodis Ioannis, Dey Dzifa, Nikiphorou Elena, Distler Oliver, Kadam Esha, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Knitza Johannes, Chinoy Hector, Aggarwal Rohit, Agarwal Vikas, Gupta Latika, COVAD Study Group
Аннотация
METHODS: A cross-sectional study was conducted among participants with self-reported new-onset SAIDs using the COVID-19 Vaccination in Autoimmune Diseases (COVAD) 2 study dataset-a validated, patient-reported e-survey-to analyze the long-term safety of COVID-19 vaccines. Baseline characteristics of patients with new-onset SAIDs and vaccinated healthy controls (HCs) were compared after propensity score matching based on age and sex in a 1:4 ratio.
RESULTS: Of 16 750 individuals, 74 (median age 52 years, 79.9% females, and 76.7% Caucasians) had new-onset SAID post-vaccination, mainly idiopathic inflammatory myopathies (IIMs) (n = 23, 31.51%), arthritis (n = 15; 20.53%), and polymyalgia rheumatica (PMR) (n = 12, 16.40%). Higher odds of new-onset SAIDs were noted among Caucasians (OR = 5.3; 95% CI = 2.9-9.7; p < .001) and Moderna vaccine recipients (OR = 2.7; 95% CI = 1.3-5.3; p = .004). New-onset SAIDs were associated with AID multimorbidity (OR = 1.4; 95% CI = 1.1-1.7; p < .001), mental health disorders (OR = 1.6; 95% CI = 1.3-1.9; p < .001), and mixed race (OR = 2.2; 95% CI = 1.2-4.2; p = .010), where those aged >60 years (OR = 0.6; 95% CI = 0.4-0.8; p = .007) and from high/medium human development index (HDI) countries (compared to very high HDI) reported fewer events than HCs.
CONCLUSION: This study reports a low occurrence of new-onset SAIDs following COVID-19 vaccination, primarily IIMs, PMR, and inflammatory arthritis. Identified risk factors included pre-existing AID multimorbidity, mental health diseases, and mixed race. Revaccination was well tolerated by most patients; therefore, we recommend continuing COVID-19 vaccination in the general population. However, long-term studies are needed to understand the autoimmune phenomena arising post-vaccination.